In addition, by Cox regression analysis, SOX30 hypermethylation was an independently adverse prognostic biomarker for OS among whole-cohort AML, non-M3 AML, and CN-AML patients (P = 0.014, 0.012, and 0.054, Additional file 1: Table S1-S3). This evidence concerns the gene SOX30 and acute myeloid leukemia.